Skip to main content
OpenTrials
Completed

NCT Number: NCT05632744

Evaluation of CG-100 Intraluminal Bypass Device

Evaluation of CG-100 Intraluminal Bypass device

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Colorectal Cancer Colonic Diseases Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Intestinal Neoplasms Neoplasms Neoplasms by Site Rectal Diseases

Age range

22 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Soroka Medical Center

Rehovot, Israel

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

(pre-operative):

  • Willing to comply with protocol-specified follow-up evaluations
  • 22-75 (inclusive) years of age at screening
  • Diagnosed with colorectal cancer
  • Has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent

Treatment and study plan

CG-100 intraluminal bypass device

Device

Subjects will be treated with the CG-100 Intraluminal Bypass Device

Primary outcomes

  1. Safety of the CG-100 Intraluminal Bypass Device

    Time frame: 10 days

    Assessment of Serious Adverse Events

Secondary outcomes

  1. Safety of the CG-100 Intraluminal Bypass Device

    Time frame: 4 weeks

    Assessment of Serious Adverse Events

Sponsors and collaborators

Lead sponsor

Colospan Ltd.

Industry

Registry information

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Dec 1, 2022
Registry last updated
Jul 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.